PMC-12, a Prescription of Traditional Korean Medicine, Improves Amyloid -Induced Cognitive Deficits through Modulation of Neuroinflammation

Figure 4

Effects of PMC-12 on cell viability and LPS-induced inflammatory mediators in BV2 microglia cells. Cells were treated with the indicated concentrations of PMC-12 (1, 3, 10, or 30 μg/mL) 1 h before LPS (1 μg/mL) treatment for 24 h (MTT reduction assays and Western blot analysis) or 6 h (RT-PCR and real-time PCR). (a) Cell viability was assessed by MTT reduction assays and the results were expressed as the percentage of surviving cells over control cells (no addition of LPS and PMC-12). (b) The expressions of iNOS and COX-2 protein and mRNA were determined by Western blot analysis and RT-PCR, respectively. (c) These data were confirmed by real-time PCR that showed PMC-12 significantly reduced the inflammatory mediators iNOS, COX-2, IL-1β, and IL-6 levels in LPS-stimulated BV2 cells. ^** versus cells without LPS (Con, control); ^# and ^## versus cells treated with LPS in the absence of PMC-12. Data shown are the means ± SEM of values from four separate experiments.

(a)

(b)

(c)